ESR1 and breast cancer: In addition, the selective estrogen receptor modulator tamoxifen (TAM, 10 nM) that is used in the adjuvant treatment of ER+ breast cancers, also reduced the migration of T47-D cells induced by E2 while being ineffective on its own (Fig. 9).